Lupin Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LUPIN, and when can generic versions of LUPIN drugs launch?
LUPIN has two hundred and forty-seven approved drugs.
There are nineteen US patents protecting LUPIN drugs. There are twenty-three tentative approvals on LUPIN drugs.
There are ninety-nine patent family members on LUPIN drugs in twenty-four countries and seven hundred and three supplementary protection certificates in seventeen countries.
Summary for Lupin
International Patents: | 99 |
US Patents: | 19 |
Tradenames: | 200 |
Ingredients: | 181 |
NDAs: | 247 |
Patent Litigation for Lupin: | See patent lawsuits for Lupin |
PTAB Cases with Lupin as petitioner: | See PTAB cases with Lupin as petitioner |
Drugs and US Patents for Lupin
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lupin Ltd | ILOPERIDONE | iloperidone | TABLET;ORAL | 206890-004 | May 5, 2022 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Lupin Pharms | MELOXICAM | meloxicam | TABLET;ORAL | 077944-001 | Jul 19, 2006 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Lupin Ltd | NIKITA | pitavastatin sodium | TABLET;ORAL | 209875-002 | Aug 4, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Lupin Ltd | LURASIDONE HYDROCHLORIDE | lurasidone hydrochloride | TABLET;ORAL | 208031-004 | Jan 3, 2019 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Lupin
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Lupin | BROVANA | arformoterol tartrate | SOLUTION;INHALATION | 021912-001 | Oct 6, 2006 | 7,473,710 | ⤷ Try a Trial |
Lupin | XOPENEX HFA | levalbuterol tartrate | AEROSOL, METERED;INHALATION | 021730-001 | Mar 11, 2005 | 5,836,299 | ⤷ Try a Trial |
Lupin | BROVANA | arformoterol tartrate | SOLUTION;INHALATION | 021912-001 | Oct 6, 2006 | 6,472,563 | ⤷ Try a Trial |
Lupin | BROVANA | arformoterol tartrate | SOLUTION;INHALATION | 021912-001 | Oct 6, 2006 | 8,110,706 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for LUPIN drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
➤ Subscribe | Injection | 250 mcg/0.5 mL, 1 mL PFS | ➤ Subscribe | 2012-03-30 |
➤ Subscribe | Inhalation Solution | Eq. 0.015 mg base/2 mL | ➤ Subscribe | 2009-10-01 |
➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
➤ Subscribe | for Oral Suspension | 500 mg/5 mL | ➤ Subscribe | 2014-07-22 |
International Patents for Lupin Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Denmark | 2292584 | ⤷ Try a Trial |
Israel | 168739 | ⤷ Try a Trial |
Eurasian Patent Organization | 031355 | ⤷ Try a Trial |
Japan | 2017019879 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Lupin Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1663240 | 59/2015 | Austria | ⤷ Try a Trial | PRODUCT NAME: KOMBINATION VON RILPIVIRIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ VON RILPIVIRIN, EINSCHLIESSLICH DES HYDROCHLORIDSALZES VON RILPIVIRIN, TENOFOVIR, INSBESONDERE TENOFOVIRDISOPROXILFUMARAT, UND EMTRICITABIN; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128 |
2435025 | CA 2019 00032 | Denmark | ⤷ Try a Trial | PRODUCT NAME: KOMBINATION AF GLYCOPYRROLAT, HERUNDER ALLE FARMACEUTISK ACCEPTABLE SALTE, ESTERE, ENANTIOMERER ELLER ANDRE DERIVATER DERAF, OG FORMOTEROL, HERUNDER ALLE FARMACEUTISK ACCEPTABLE SALTE, ESTERE, ENANTIOMERER ELLER ANDRE DERIVATER DERAF; REG. NO/DATE: EU/1/18/1339 20181220 |
0720599 | 300689 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ATORVASTATINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ATORVASTATINE CALCIUM TRIHYDRATE; NATIONAL REGISTRATION NO/DATE: RVG114373-114376 20141027; FIRST REGISTRATION: FR 2014091200122 20140912 |
1412357 | 132008901682802 | Italy | ⤷ Try a Trial | PRODUCT NAME: SITAGLIPTIN/METFORMINA CLORIDRATO(JANUMET, VELMETIA, EFFICIB); AUTHORISATION NUMBER(S) AND DATE(S): JANUMET:EU/1/08/455/001... 014; VELMETIA:EU/1/08/456/001...014;EFFICIB: EU/1/08/457/001....014, 20080716;58450-01;58450-02; 58450-03, 20080408 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.